Table 1.
Patient characteristics (ITT)
| Characteristic | Asian (Non-South) | South Asian | Caucasian | P value |
|---|---|---|---|---|
| Number of subjects | 39 (10%) | 34 (9%) | 319 (81%) | |
| Age (years) | 51.5 ± 11.0 | 46.7 ± 11.2 | 49.4 ± 9.2 | 0.105 |
| No. of males | 21 (54%) | 23 (68%) | 215 (67%) | 0.236 |
| Genotype | ||||
| 1 | 32 (82%) | 5 (15%) | 223 (70%) | <0.001 |
| 2 | 5 (13%) | 2 (6%) | 43 13%) | |
| 3 | 2 (5%) | 27 (79%) | 53 (17%) | |
| Pretreatment viral load (log10 IU/ml) | 6.0 ± 0.6 | 5.9 ± 0.8 | 5.8 ± 0.6 | 0.418 |
| Weight (kg) | 59.6 ± 12.0 | 74.9 ± 12.9 | 80.4 ± 15.6 | <0.001 |
| BMI (kg/m2) | 22.4 ± 3.5 | 27.5 ± 4.8 | 27.4 ± 4.9 | <0.001 |
| Obese (WHO definition) | 0 (0%) | 7 (27%) | 69 (24%) | <0.001 |
| Obese (Asian definition) | 3 (9%) | 15 (58%) | 69 (24%) | <0.001 |
| Diabetes (type 1 or 2) | 7 (18%) | 6 (18%) | 24 (8%) | 0.021 |
| Advanced fibrosis (F3–F4 or clinical features of cirrhosis) | 22 (59%) | 15 (48%) | 171 (58%) | 0.577 |
| Steatosis ≥10% | 5 (16%) | 15 (60%) | 73 (27%) | 0.001 |
| Treatment naïve status | 33 (85%) | 33 (97%) | 263 (82%) | 0.064 |
| PegIFN 2a | 18 (46%) | 15 (44%) | 200 (63%) | 0.023 |
| Calculated ribavirin dose received (mg/kg/day) | 15.0 ± 3.0 | 12.7 ± 2.3 | 12.6 ± 2.4 | <0.001 |
| Received “adequate” therapy (>80% dose, 80% duration) | 34 (87%) | 33 (97%) | 275 (86%) | 0.203 |
Data are expressed as n (%) or mean ± SD